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Cyclooxygenase 2 (Cox-2) is upregulated in colorectal adenomas and carcinomas. Polymorphisms in the Cox-2 gene may influence its
function and/or its expression and may modify the protective effect of nonsteroidal anti-inflammatory drugs (NSAIDs), thereby
impacting individuals’ risk of developing colorectal cancer and response to prevention/intervention strategies. In a nested case–
control study, four polymorphisms in the Cox-2 gene (two in the promoter,  663 insertion/deletion, GT/(GT) and  798 A/G; one in
intron 5-5229, T/G; one in 30untranslated region (UTR)-8494, T/C) were genotyped in 726 cases of colorectal adenomas and 729
age- and gender-matched controls in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. There was no
significant association between the Cox-2 polymorphisms and adenoma development in the overall population. However, in males,
the relatively rare heterozygous genotype GT/(GT) at  663 in the promoter and the variant homozygous genotype G/G at intron 5-
5229 appeared to have inverse associations (odds ratio (OR)¼0.59, confidence interval (CI): 0.34–1.02 and OR¼0.48, CI: 0.24–
0.99, respectively), whereas the heterozygous genotype T/C at 30UTR-8494 had a positive association (OR¼1.31, CI: 1.01–1.71)
with adenoma development. Furthermore, the haplotype carrying the risk-conferring 30UTR-8494 variant was associated with a 35%
increase in the odds for adenoma incidence in males (OR¼1.35, CI: 1.07–1.70), but the one with a risk allele at 30UTR-8494 and a
protective allele at intron 5-5229 had no effect on adenoma development (OR¼0.85, CI: 0.66–1.09). Gender-related differences in
adenoma risk were also noted with tobacco usage and protective effects of NSAIDs. Our analysis underscores the significance of the
overall allelic architecture of Cox-2 as an important determinant for risk assessment.
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Upregulation of the inducible isoform of prostaglandin endoper-
oxide G/H synthase/cyclooxygenase enzyme, PTGS2 or cycloox-
ygenase 2 (Cox-2), occurs in various cancers (Prescott and
Fitzpatrick, 2000). Cyclooxygenase 2 generates multifunctional lipid
metabolites, prostaglandins, which are implicated in various cellular
processes including proliferation, inflammation, invasion, angio-
genesis, and apoptosis (Cao and Prescott, 2002). It is estimated that
more than 85% of human colon cancers and 50% of colorectal
adenomas have elevated levels of Cox-2 (Eberhart et al,1 9 9 4 ) .
In mouse models of colorectal carcinoma, disruption of the
Cox-2 gene as well as its selective inhibition resulted in a decreased
number of polyps (Oshima et al, 1996; Mahmoud et al, 1998;
Jacoby et al, 2000). Nonsteroidal anti-inflammatory drugs
(NSAIDs), which inhibit both the constitutively expressed Cox-1
and inducible Cox-2, show a protective effect in numerous
epidemiological studies for the incidence of colorectal cancer
(Giovannucci et al, 1995; Smalley et al, 1999). Results from recent
randomised clinical trials also demonstrated that aspirin prevented
the recurrence of adenoma polyps (Baron et al, 2003; Benamouzig
et al, 2003; Sandler et al, 2003). Celecoxib, a selective inhibitor of
Cox-2, was shown to have chemopreventive effects in the clinical
trial of familial adenomatous polyposis patients (Steinbach et al,
2000). Despite considerable heterogeneity in the response of
individual patients to celecoxib, there was a significant reduction
in the overall polyp burden. Thus, it appears that the expression
and activity of Cox-2 have a major role in colon carcinogenesis.
A large number of polymorphisms affecting coding as well as
noncoding regions of Cox-2 have been reported. Genetic variants
of Cox-2 with nonsynonymous single-nucleotide polymorphisms
(SNPs) in the coding region may have altered specificity, function,
and/or interaction with NSAIDs, and may contribute to colorectal
cancer risk. However, the frequency of nonsynonymous SNPs in
the Cox-2 gene, especially in Caucasians, is very low. The
expression and/or stability of Cox-2 can also be affected by
polymorphisms in the regulatory regions that include the
promoter, intronic regions, and the 30untranslated region (UTR).
Genetic variants of Cox-2 in these regions have been reported
previously. A common promoter variant,  765 G/C (rs20417/
ss5112606), which is located in the putative Sp1 binding site, was
reported to have reduced promoter activity and was associated
with reduced plasma C-reactive protein levels with implications for
various inflammatory responses (Papafili et al, 2002) and with a
decreased risk for myocardial infarction and stroke (Cipollone
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set al, 2004). Pima Indians with the variant homozygote genotype at
this promoter polymorphism (reported as  899 G/C, rs20417/
ss5112606) were found to have a 30% higher prevalence of type II
diabetes mellitus (Konheim and Wolford, 2003). Recently, allelic
variations in the Cox-2 gene have been analysed for their
association with cancer development. Polymorphisms in the
promoter and 30UTR of the Cox-2 gene were found to modulate
risk for prostate, colorectal, and non-small-cell lung carcinoma
(Campa et al, 2004; Cox et al, 2004; Panguluri et al, 2004).
Polymorphisms may also modify the effect of NSAIDs in the
prevention of colon cancer and adenomas. Two reports have
shown the pharmacological relevance of the polymorphism P17L
in the Cox-1 gene and NSAIDs usage, albeit with opposite
associations (Halushka et al, 2003; Ulrich et al, 2004). There is
limited data on the interaction between Cox-2 SNPs and NSAIDs.
More recently, the wild-type and variant genotypes at the  765
position (rs20417/ss5112606) in the promoter region were reported
to decrease the risk of colorectal polyp formation in users and
nonusers of aspirin/NSAIDs, respectively (Ulrich et al, 2005).
In this study, we explored the association between four specific
SNPs in the regulatory regions (two in the promoter region ( 663
and  798), one in intron 5 (5229), and one in 30UTR (8494)) and
the risk for advanced adenoma in a nested case/control study of
1455 Caucasians (726 cases and 729 controls) from the prostate,
lung, colorectal, and ovarian (PLCO) cancer screening trial
(Gohagan et al, 2000). Furthermore, in view of the strong evidence
of tobacco smoking as a risk factor and use of NSAIDs as a
protective factor for colorectal cancer, we investigated possible
interactions between Cox-2 gene polymorphisms and the smoking
status and use of NSAIDs on the risk of adenoma development.
MATERIALS AND METHODS
Study population
The study was conducted using a nested case–control design
within the PLCO cancer screening trial, which was designed to
evaluate the impact of selected screening procedures on PLCO
cancer mortality. The trial recruited approximately 74000 screen-
ing arm participants (37000 men, 37000 women; age 55–74 years)
and an equal number of nonscreened controls, aged 55–74 years,
at 10 US study centres. Participants were randomised to the
screening or control arms to evaluate the effect of blood prostate-
specific testing and digital rectal examination, chest X-ray,
sigmoidoscopy, and trans-vaginal ultrasound and CA-125 testing
on PLCO cancer mortality (Gohagan et al, 2000). Written informed
consent from participants and approval from the institutional
review boards of the 10 study centres and National Cancer Institute
were obtained. Detailed information on diet, tobacco and alcohol
use, intake of selected drugs, family history of cancer, and other
risk factors were obtained with a baseline questionnaire.
In this nested case–control study, 726 (506 males and 220
females) individuals with advanced adenomas and 729 (502 males
and 227 females) screen-negative gender-matched controls were
selected from the screening arm of the trial. The disparity between
the number of males and females may partially be due to the initial
slow accrual of women as bilateral oophorectomy was originally an
exclusion criterion (dropped later) (Weissfeld et al, 2005). More
importantly, it is a reflection of substantially greater prevalence of
large (X1.0cm), intermediate (0.5–0.9cm), or any size polyp in
men than in women; cancer and advanced adenomas were also
diagnosed twice as frequently in men in the PLCO trial (Weissfeld
et al, 2005). Advanced adenoma was defined as villous or
tubulovillous adenoma, large adenoma (41.0cm), or severe or
high-grade dysplasia. The screen-negative controls had no polyp
or other suspect lesions. Characteristics of this study population
have been described previously (Huang et al, 2005). All cases and
controls used in this analysis were of Caucasian origin.
Genotyping
The following four polymorphisms in the Cox-2 gene, with
reasonable frequency distribution in Caucasians, were selected to
be analysed for their association with adenoma development: (1)
GT insertion/deletion polymorphism at position  663 (positions
refer to the Genbank entry AY382629 and http://pga.gs.washington.
edu/data/ptgs2/ptgs2.ColorFasta.html) in the promoter with a
frequency of deletion: 0.10, (2) A/G polymorphism at position
 798 in the promoter with a frequency of G: 0.11, (3) T/G
polymorphism at position 5229 in intron 5 with a frequency of G:
0.35, and (4) T/C polymorphism at position 8494 in the 30UTR with
a frequency of C: 0.43. All four polymorphisms were genotyped
using the ABI Prism sequence detector (TaqMan; PE Biosystems,
Foster City, CA, USA). Polymerase chain reaction primers and
dual-labelled allele discrimination probes were designed using the
Primer Express software package (PE Biosystems). Oligonucleotide
probes were labelled with two different fluorescent dyes, FAM
TM
and VIC
TM, to discriminate between the two alleles of the
polymorphism. Primer and probe sequences for the four
polymorphisms are displayed in Table 1.
The assay was set up in 25ml reactions with 1–5ng of genomic
DNA and 2 volume of the Master Mix provided by PE
Biosystems, which contains all four deoxynucleotides, Taq
polymerase and TaqMan buffer, 2000nm of forward and reverse
primers, and the double-labelled probes. The thermal cycling
conditions for the ABI prism 7700 Sequence Detector were set up
at initial settings of 501C for 10min followed by 40 cycles each of
951C for 15s and 601C for 1min. In each 96-well plate, internal
quality controls for homozygous wild-type, heterozygous, and
homozygous variant alleles for the respective polymorphism and
no template controls were included. Additionally, approximately
Table 1 Polymorphisms, primers, and probes
Polymorphism dbSNP Forward primer Reverse primer FAM
TM probe VIC
TM probe
–663 GT (insertion/deletion) rs68946 aggacttaggacataactg ggagcatgtcagggtga ttttctggtgtgtgtgtat ttcttttctggtgtgtgtata
aattttctatt gatact
–798 A-G rs68946 catgatagatgttaaataa tggaacatagttggatga aaattccagctgtcaaa aattccaactgtcaaaat
aagcaaaga ggaattaat
5229 T-G rs20432 ttttataaataatacattt aacggaattaatatactat atacttttttagaattac atacttttttataattacca
attgagcttatatcatata catatc tatca
8494 T-C rs5275 catcttccatgatgcatta aataatgcactgatacct tgacagaaaaataac aaaatgaccaaaagtac
gaagtaa gtttt caaaa
dbSNP, single nucleotide polymorphism database. Numbers refer to positions of polymorphisms in the Genbank entry AY382629 and as detailed at http://pga.gs.washington.edu/
data/ptgs2/ptgs2.ColorFasta.html.
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personnel were blind to the status of the samples.
Statistical analysis and haplotype construction
Odds ratios (ORs) were estimated using regression models using
PROC LOGISTIC function of the software package SAS (version
8.1; SAS Institute, Cary, NC, USA), adjusting for age, gender,
tobacco use, and NSAIDs use. The asymptomatic Pearson’s w
2 test
was used to assess departure from Hardy–Weinberg equilibrium
by comparing the expected to observed genotype frequencies. All
polymorphisms were in Hardy–Weinberg equilibrium, except the
one at intron 5-5229. The reasons for this deviation are not clear;
however, it is highly unlikely to be due to genotyping errors as the
inclusion of the internal and external controls, and the blindedness
of the laboratory personnel to the samples ensured accuracy of
genotyping results. The possibility that deviation from Hardy–
Weinberg at this one position could be due to bias in selection of
the controls cannot be ruled out.
Since no homozygous variant at  663 was present and no
association was found for the genotypes at  798, haplotypes
incorporating only the intron 5-5229 and 30UTR-8494 genotypes
were constructed using the PHASE version 2 software (Stephens
et al, 2001; Stephens and Donnelly, 2003). Only the haplotypes with
known genotypes were used and no inferred haplotypes were
included in the analysis.
RESULTS
Association of Cox-2 polymorphisms with adenoma
development
Among the subjects analysed in this study, approximately 70%
were male. This is consistent with the 2:1 ratio of the incidence of
colon polyps and tumours in the PLCO trial (Weissfeld et al, 2005)
as well as reported elsewhere (McCashland et al, 2001). The initial
assessment of the entire study population detected only trends
between certain genotypes and the disease, but no statistically
significant associations. We therefore performed association
analyses on males and females separately and observed significant
gender-based differences. Table 2 displays the association of Cox-2
genotypes with the risk for advanced adenomas in all subjects and
in males and females after standardising for age and smoking
history. In males, the heterozygous genotype at  663 with a GT
deletion, although infrequent, and the variant homozygotes at the
intron 5-5229 positions suggest a decrease in the risk of developing
adenomas (OR¼0.59, 95% confidence interval (CI): 0.34–1.02 and
OR¼0.48, 95% CI: 0.24–0.99, respectively). On the other hand,
individuals with the heterozygous genotype at 30UTR-8494 were at
an increased risk for developing advanced adenomas (OR¼1.31,
CI: 1.01–1.71). The OR of 1.02 for the homozygous variant
genotype was also in the same direction, but may not have reached
significance because of relatively small number compared to the
individuals with the heterozygous genotype.
There was no association between the genotypes at any of the
four polymorphic sites in the Cox-2 gene and advanced adenomas
in females. However, it is of note that the heterozygous and variant
homozygous genotypes at intron 5-5229 showed a trend toward
positive association with adenoma risk compared to the suggested
protective effect in males. The ORs of genotypes at the  798 and
30UTR-8494 positions in females, on the other hand, appeared to
follow the same trend as in males (Table 2).
The two polymorphisms of the Cox-2 gene with reasonable
frequency and with an association with adenoma development in
males, that is, intron 5-5229 and 30UTR-8494, were used
to construct haplotypes using the PHASE program. Three
haplotypes, TT, TC, and GC, accounted for 99.6% of all
chromosomes. As shown in Table 3, the haplotype TC, which
carried the risk allele at the 30UTR-8494 position, was more
common in cases than in controls with a 26% increased risk of
adenomas in all subjects (OR¼1.26, 95% CI: 1.03–1.53) and with a
35% increased risk of adenomas in males (OR¼1.35, 95% CI:
1.07–1.70) compared to the wild-type haplotype of TT. The
haplotype was not significant in females. The risk effect of the
haplotype TC was neutralised in the haplotype GC, which
harboured the protective allele at intron 5-5229 (All, OR¼0.95,
95% CI: 0.77–1.16; Males, OR¼0.85, 95% CI: 0.66–1.09), showing
that the risk of adenoma is determined by the cumulative effects of
both polymorphisms. Essentially, the same results were obtained
when haplotypes were constructed incorporating all four poly-
morphisms analysed in this study (data not shown). The effect of
Table 2 Cox-2 genotypes and risk of advanced colorectal adenomas
All Males Females
Genotypes Cases/controls
OR
95% CI Cases/controls
OR
95% CI Cases/controls
OR
95% CI
 663
GT/GT 702/704 490/478 212/226
GT/(GT)
a 32/45 0.65 (0.40, 1.04) 24/36 0.59 (0.34, 1.02) 8/9 0.95 (0.35, 2.5)
 798
A/A 490/493 339/340 151/153
A/G 233/231 1.017 (0.81, 1.27) 167/158 1.06 (0.81, 1.39) 66/73 0.91 (0.60, 1.37)
G/G 18/26 0.80 (0.43, 1.50) 11/16 0.79 (0.35, 1.76) 7/10 0.82 (0.30, 2.27)
5229
T/T 534/530 384/363 150/167
T/G 189/190 0.94 (0.74, 1.20) 125/130 0.88 (0.66, 1.18) 64/60 1.15 (0.75, 1.77)
G/G 24/33 0.73 (0.42, 1.27) 13/23 0.48 (0.24, 0.99) 11/10 1.43 (0.58, 3.55)
8494
T/T 311/347 215/244 96/103
T/C 344/318 1.17 (0.94, 1.46) 249/211 1.31 (1.01, 1.71) 95/107 0.94 (0.63, 1.41)
C/C 94/91 1.14 (0.82, 1.59) 59/64 1.02 (0.68, 1.53) 35/27 1.40 (0.78, 2.53)
OR¼odds ratio; CI¼confidence interval. Adjusted for age and smoking history.
aParentheses refers to deletion polymorphism.
Cox-2 allelic variants and colorectal adenoma
IU Ali et al
955
British Journal of Cancer (2005) 93(8), 953–959 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sthe rare deletion polymorphism at  663, which had a negative
association with adenomas in males, could not be determined in
the context of haplotype as the only haplotype carrying the  663
variant allele was relatively rare.
Cox-2 genotypes and tobacco smoking
The use of tobacco is considered to be a risk factor for colorectal
cancer. There was a positive association between cigarette smoking
and development of aggressive adenomas in the study population,
especially a highly significant association between current
smokers, both males (OR¼2.50, 95% CI: 1.54–4.04) and females
(OR¼2.51, CI: 1.31–4.80), and risk of colorectal adenoma, when
adjusted for age and NSAID use. We assessed the main effect of all
four Cox-2 genotypes on adenoma development when individuals
were stratified by smoking status and adjusted for age and NSAIDs
usage. Most of the genotypes, especially in current smokers, were
associated with a relative increase in the risk of colon cancer
compared to never smokers in both males and females (data not
shown). Table 4 displays the risk of adenoma development with
tobacco usage in the context of haplotypes constructed with intron
5-5229 and 30UTR-8494 polymorphisms. Compared to never
smokers, all three haplotypes had increased risk of adenoma in
current female smokers. In current male smokers, carriers of T/T
and TC haplotypes were at significantly increased risk of adenoma
development, but the ones carrying the haplotype GC with the
protective variant at intron 5-5229 did not have a significantly
increased risk of adenoma development (OR¼1.38, CI: 0.63–
3.01). Former male smokers with the haplotype carrying the risk
variant at 30UTR-8494 appeared to be at an increased risk of
adenoma development compared to never smokers, whereas the
risk for advanced adenoma was not significant in former female
smokers with all three haplotypes.
Cox-2 genotype and use of NSAIDs
The use of NSAIDs, aspirin, and ibuprofen, which inhibit Cox-2,
was not protective for adenoma development in the study
population. When analysed at the haplotype level, the use of
aspirin was protective for individuals carrying the Cox-2 haplotype
with the wild-type alleles at both intron 5-5229 and 30UTR-8494
positions (OR¼0.74, CI: 0.57–0.95); especially the protection from
the use of aspirin in combination with ibuprofen was highly
significant (OR¼0.55, CI: 0.40–0.77) (Table 5). The use of aspirin
appeared to be protective also in male carriers of the haplotype GC,
although it did not quite reach statistical significance (OR¼0.69,
CI: 0.45–1.05). The only striking finding was the use of aspirin in
females with the GC haplotype carrying variant alleles at intron
5-5229 and 30UTR-8494 was associated with increased risk of
adenoma development. Although the numbers of cases and
controls using aspirin were small, the risk association was
statistically significant (OR¼2.40, CI: 1.06–5.40).
DISCUSSION
Analysis of potentially functional polymorphisms in candidate
genes has emerged as a powerful approach in deciphering the
complex relationship between genotype and phenotype. In this
context, association analyses can be used to explore the role of
Table 3 Haplotype frequencies constructed by PHASE algorithm in cases and controls, adjusted for age and smoking history
Haplotype
All Males Females
Intron 5-5229 and 30UTR-8494 Cases/controls
OR
95% CI Cases/controls
OR
95% CI Cases/controls
OR
95% CI
TT 959/1006 676/694 283/312
TC 298/247 1.26 (1.03, 1.53) 217/165 1.35 (1.07, 1.70) 81/82 1.06 (0.74, 1.51)
GC 234/253 0.950 (0.77, 1.16) 150/174 0.85 (0.66, 1.09) 84/79 1.200 (0.84, 1.71)
OR¼odds ratio; CI¼confidence interval. Adjusted for age and smoking history. Almost identical results were obtained using the PL-EM and SNPHAP algorithms.
Table 4 Cox-2 haplotypes and risk for advanced colorectal adenomas in association with tobacco usage
Haplotype
Never smoker Current smoker Former smoker
Intron 5-5229 and &30UTR-8494 Cases/controls
OR
95% CI Cases/controls
OR
95% CI Cases/controls
OR
95% CI
All
TT 377/458 142/63 3.12 (2.24, 4.36) 440/485 1.13 (0.93, 1.38)
TC 111/109 1.24 (0.92, 1.68) 42/16 3.71 (2.03, 6.77) 145/122 1.50 (1.13, 1.99)
GC 89/124 0.86 (0.63, 1.17) 25/18 1.83 (0.97, 3.45) 120/111 1.33 (0.99, 1.79)
Males
TT 228/274 97/49 2.81 (1.89, 4.18) 351/371 1.20 (0.95, 1.52)
TC 76/64 1.41 (0.96, 2.07) 28/11 3.76 (1.80, 7.83) 113/90 1.64 (1.17, 2.29)
GC 47/73 0.74 (0.49, 1.12) 15/13 1.38 (0.63, 3.01) 88/88 1.28 (0.90, 1.82)
Females
TT 149/184 45/14 4.45 (2.32, 8.51) 89/114 1.00 (0.70, 1.43)
TC 35/45 0.99 (0.60, 1.64) 14/5 3.82 (1.32, 11.0) 32/32 1.25 (0.72, 2.15)
GC 42/51 1.05 (0.65, 1.68) 10/5 3.10 (1.01, 9.48) 32/23 1.73 (0.96, 3.12)
OR¼odds ratio; CI¼confidence interval. Adjusted for age and NSAIDs usage.
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response to specific chemopreventive agents. In our study, analysis
of four haplotype-tagging SNPs in the regulatory regions scattered
over the entire Cox-2 gene revealed important aspects of its allelic
structure with consequences for adenoma risk and interactions
with NSAIDs.
Cox-2 is an inducible enzyme and its expression and stability
appear to be subjected to very complex mechanisms regulated by
various elements in both the 50UTR and 30UTR of the transcript as
well as intronic sequences (Dixon et al, 2000; Kirtikara et al, 2000;
Finkbeiner, 2001; Tanabe and Tohnai, 2002; Konheim and
Wolford, 2003). Several promoter elements, such as CRE as well
as those specific for binding to a variety of nuclear regulatory
factors including NfkB, NF-IL6, and myb, may play an important
regulatory role in the transcription of the Cox-2 gene in a tissue-
specific manner (Potter et al, 2000; Mestre et al, 2001; Tang et al,
2001). Polymorphisms may either eliminate or create binding
sites for various factors potentially altering the expression of
Cox-2 and thereby modulating the risk for various cancers.
Recently, four SNPs in the promoter region of Cox-2 ( 297,  899,
 1265,  1285), different from the ones used in our study, have
been described to modulate the risk for prostate cancer in
both African Americans and Caucasian individuals (Panguluri
et al, 2004).
We examined two promoter polymorphisms,  663 and  798,
the Cox-2 gene which are not located in binding sites of any known
transcription factors. The homozygous variant at  663 was
extremely rare in our study cohort, but the heterozygous genotype
was clearly protective for adenoma risk in males (Table 2). Our
data also show that the variant allele at intron 5-5229 reduced the
risk for adenoma development in males and, when analysed in the
context of haplotype, neutralised the risk effect of the 30UTR-8494
variant allele. Therefore, either the intron 5-5229 polymorphism
itself or another polymorphism that is in linkage disequilibrium
with intron 5-5229 in the Cox-2 gene may be relevant for its
transcriptional regulation and/or stability.
Besides the promoter and intronic sequences, elements in the
30UTR play an important role in polyadenylation, nuclear export,
degradation, stabilisation, and translation of the transcripts
(Kuersten and Goodwin, 2003). Binding of translational regulatory
factors to ARE (AU-rich element) in 30UTR has been shown to
alter Cox-2 expression (Dixon, 2004). In vitro experiments have
shown that overexpression of trans-activating cellular factors,
which bind to Cox-2 ARE, stabilise mRNA resulting in increased
expression of Cox-2 in colon cancer cells (Dixon et al, 2000, 2001,
2003). Conceivably, polymorphisms in the 30UTR of Cox-2 may
modify the binding affinity of regulatory factors and influence its
stability and expression. The 30UTR-8494 polymorphism analysed
here is located in the AU-rich region that mediates transcript
degradation. Our finding that the 8494 variant allele increases the
risk for colorectal adenomas in males by 31% suggests that the
polymorphism has a transcript-stabilising function. Interestingly,
the same 30UTR-8494 polymorphism was recently reported to
carry an enhanced risk for lung cancer (Campa et al, 2004),
suggesting its significance in the regulation of Cox-2 transcripts
and the subsequent impact on multiple cancers. However, the
same polymorphism did not show an effect on colorectal cancer in
another recent report, although two downstream SNPs were
associated with an increased risk (Cox et al, 2004). This lack of
association of the 30UTR-8494 polymorphism with colorectal
cancer risk (Cox et al, 2004) could be due to relatively small
number of subjects (292 cases/274 controls) and/or analysing
males and females together. In any event, association of the 30UTR-
8494 variant and/or nearby polymorphisms in colorectal and lung
carcinogenesis warrant a closer look at this region for its role in
post-transcriptional regulation of the Cox-2 gene with implications
for colorectal and lung carcinogenesis.
In our study, sequence variations in the Cox-2 gene, with a
potential to affect its expression and/or stability, appear to
modulate the risk for adenoma development only in males.
Previous studies have documented gender differences in the
incidence, location, and pathogenesis of colonic adenomatous
polyps and tumours (DeCosse et al, 1993; McCashland et al, 2001;
Weissfeld et al, 2005). The reduced colorectal cancer risk in
women has been attributed to physiological, environmental, and
behavioural factors (DeCosse et al, 1993). Especially, oestrogen has
been suggested to have a protective role in colon carcinogenesis by
affecting metabolism of bile acids and serum levels of insulin-like
growth hormone levels (Everson et al, 1991; Campagnoli et al,
1993). Transcriptional silencing of the oestrogen receptor gene has
been reported in colorectal tumours (Issa et al, 1994) and a meta-
analysis of several epidemiological studies of postmenopausal
women reported a significant reduction in the risk of colorectal
cancers with hormone therapy (Grodstein et al, 1999). The
apparent lack of any role of Cox-2 polymorphisms in the
development of adenomas in females noted in our study could
simply be due to relatively small numbers analysed and certainly
needs further validation. A comprehensive analysis of various Cox-
2 haplotypes in a much larger case–control study comprising of
females would help clarify this issue.
Table 5 Cox-2 haplotypes and risk for advanced colorectal adenomas in association with NSAIDs use
Haplotype
None Aspirin Ibuprofen Both
Intron 5-5229 and
30UTR-8494
Cases/
controls
OR
95% CI
Cases/
controls
OR
95% CI
Cases/
controls
OR
95% CI
Cases/
controls
OR
95% CI
All
TT 422/397 301/302 0.87 (0.70, 1.07) 106/121 0.83 (0.61, 1.12) 132/186 0.65 (0.50, 0.85)
TC 123/102 1.11 (0.82, 1.5) 101/68 1.30 (0.92, 1.82) 34/31 1.03 (0.62, 1.73) 40/46 0.81 (0.51, 1.27)
GC 97/111 0.77 (0.56, 1.0) 73/67 0.92 (0.61, 1.32) 25/34 0.69 (0.404, 1.195) 39/41 0.93 (0.58, 1.48)
Males
TT 309/266 222/236 0.742 (0.57, 0.95) 61/67 0.78 (0.52, 1.15) 84/125 0.55 (0.40, 0.77)
TC 91/64 1.18 (0.82, 1.7) 77/52 1.17 (0.79, 1.74) 20/16 1.09 (0.55, 2.18) 29/33 0.75 (0.44, 1.28)
GC 60/74 0.64 (0.44, 0.9) 53/57 0.69 (0.45, 1.05) 13/20 0.59 (0.28, 1.22) 24/23 0.92 (0.50, 1.69)
Females
TT 113/131 79/66 1.32 (0.87, 2.00) 45/54 0.98 (0.610, 1.583) 48/61 0.90 (0.57, 1.43)
TC 32/38 0.96 (0.55, 1.6) 24/16 1.66 (0.83, 3.31) 14/15 1.04 (0.47, 2.28) 11/13 0.93 (0.39, 2.20)
GC 37/37 1.11 (0.65, 1.8) 20/10 2.40 (1.06, 5.40) 12/14 0.90 (0.39, 2.06) 15/18 1.01 (0.48, 2.13)
OR¼odds ratio; CI¼confidence interval. Adjusted for age and smoking history.
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significance of the overall allelic architecture of Cox-2 on disease
risk rather than its effect based on individual SNPs in isolation.
Among the four polymorphisms analysed, the combination and/or
interplay between two SNPs (minor allele frequencies of 0.35 and
0.43 for intron 5-5229 and 30UTR-8494, respectively) were
important in determining the risk of developing colorectal
adenomas. The allelic influence of these two individual poly-
morphisms conferring either risk of or protection from adenoma
development was neutralised in individuals carrying both variants
(Table 3).
Cyclooxygenase 2 is a primary target for NSAIDs, which have
been shown to reduce the risk of colon cancers and colorectal
adenomas. Aspirin use was associated with a decrease in the
recurrence of colorectal adenomas in randomised clinical trials
(Baron et al, 2003; Benamouzig et al, 2003; Sandler et al, 2003).
Sequence variations in the Cox-2 gene could conceivably modify
the chemopreventive effect of aspirin (Ulrich et al, 2005) and
possibly other NSAIDs. In our analysis, the Cox-2 haplotype with
wild-type alleles of intron 5-5229 and 30UTR-8494 (also of  663
and  798, data not shown) was pharmacologically beneficial in
males (Table 5). The GC haplotype carrying the protective and risk
alleles was also suggestive of a beneficial effect in male aspirin
users. On the contrary, not only that females do not appear to
drive any benefit from aspirin use, female carriers of the GC
haplotype were at a significantly increased risk for adenoma
development. Of cautionary note here is, the increased risk,
although significant, was based on small number of female aspirin
users with the GC haplotype.
The gender difference has also recently been reported in the
cardiovascular response to aspirin. The risk of myocardial
infarction or death from cardiovascular causes in women was
not altered by aspirin but was significantly reduced in men
(Steering Committee of the Physicians’ Health Study Research
Group, 1989; Levin, 2005; Ridker et al, 2005). Our preliminary
observation of the harmful effect of aspirin on colorectal adenoma
in females, if confirmed in a larger study, would be helpful in
pharmacological stratification of patients according to the Cox-2
haplotypes.
Cyclooxygenase 2 is a crucial enzyme in a key signalling
pathway and has been the target of prevention/intervention
strategies in many clinical trials. Selective inhibition of Cox-2
results in variable responses in individual patients. An exhaustive
approach using the haplotype-defining SNPs in the gene as well as
information on the functional significance of polymorphisms with
the risk-modulating ability would have significant implications not
only for risk identification but also for pharmacological manage-
ment of the disease.
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